Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47239Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 林峰輝(Feng-Huei Lin) | |
| dc.contributor.author | Cheng Chen | en |
| dc.contributor.author | 陳正 | zh_TW |
| dc.date.accessioned | 2021-06-15T05:51:56Z | - |
| dc.date.available | 2013-08-20 | |
| dc.date.copyright | 2010-08-20 | |
| dc.date.issued | 2010 | |
| dc.date.submitted | 2010-08-17 | |
| dc.identifier.citation | World Health Organization. (2009). Mental Health – Depression. Retrieved July 21, 2009, from http://www.who.int/mental_health/management/depression/definition/en/
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 62 (6), 617-627. Kessler R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association, 289 (23), 3095-3105. National Policy Foundation. (2004). NPF Commentary. Retrieved July 3, 2009, from http://old.npf.org.tw/PUBLICATION/SS/093/SS-C-093-015.htm Depression Guideline Panel. (1993). Depression in primary care: volume 1 – Detection and diagnosis. AHCPR Pub. No. 93 0551. Rockville: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research. Substance Abuse and Mental Health Service Administration. (2007). National Survey of Drug Use and Health. Bastiaens, L. (2004). Response to Antidepressant Treatment in a Community Mental Health Center. Community Mental Health Journal, 40 (6), 561-567. The Brown University Long-Term Care Quality Advisor. (1997). July 14, vol. 9, (13), 5. Mayo Clinic. (2008). Depression (major depression) – Prevention. July 2, 2009, from http://www.mayoclinic.com/health/depression/DS00175/DSECTION=prevention First, M. B., & Tasman, A. (2004). DSM-IV-TR Mental Disorders: Diagnosis, Etiology and Treatment. England: John Wiley & Sons, Ltd. Mayes, R., & Horwitz, A. V. (2005). DSM-III and the revolution in the classification of mental illness. Journal of the History of the Behavioral Sciences, 41 (3), 249–267 Deprssion.com. (2009). Causes of Depression. Retrieved July 15, 2009, from http://www.depression.com/causes_of_depression.html Healthy Place – America’s Mental Health Channel. (2009). Causes of Depression. Retrieved August 20, 2009, from http://www.healthyplace.com/depression/main/causes-of-depression/menu-id-943/ Depression-Guide. (2005). Severity. Retrieved July 15, 2009, from http://www.depression-guide.com/severity.htm World Health Organization. (2007). International Statistical Classification of Diseases and Related Health Problems, 10th Version. Retrieved July 20, 2009, from http://apps.who.int/classifications/apps/icd/icd10online/ Cleveland Clinic. (2009). Treatment Options for Depression. Retrieved August 20, 2009, from http://my.clevelandclinic.org/disorders/Depression/hic_Treatment_Options_for_Depression.aspx WebMD. (2009). Depression Treatment Options. Retrieved August 21, 2009, from http://www.webmd.com/depression/guide/depression-treatment-options How Antidepressants Work. (2009). Duke University Medical Center. Teen Depression. (2005). Antidepressants. Retrieved August 25, 2009 from http://www.teendepression.org/articles52.html Weber, M. M., & Emrich, H. M. (1988). Current and Historical Concepts of Opiate Treatment in Psychiatric Disorders. International Clinical Psychopharmacology, 3 (3), 255–266. Barlow, D. H., & Durand, V. M. (2009). Chapter 7: Mood Disorders and Suicide. Abnormal Psychology: An Integrative Approach, 5th ed. Belmont, CA: Wadsworth Cengage Learning. Preskorn, S. H., Ross, R., & Stanga, C. Y. (2004). Selective Serotonin Reuptake Inhibitors. Antidepressants: Past, Present and Future. Berlin: Springer, 241–262. Dorell, K., Cohen, M. A., Huprikar, S. S., Gorman, J. M., & Jones, M. (2005). Citalopram-induced diplopia. Psychosomatics, 46 (1). 91–93. Höschl, S., & Švestka, J. (2008). Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics, 8 (4), 537-552. Wong, D. T., Perry, K. W., & Bymaster, F. P. (2005). The Discovery of Fluoxetine Hydrochloride (Prozac). Nature Reviews Drug Discovery (Nature), 4 (9), 764–774. McClellan, K. J., & Figgitt, D. P. (2000). Fluvoxamine – An Updated Review of its Use in the Management of Adults with Anxiety Disorders. Adis Drug Evaluation, 60 (4), 925–954. Barbui, C., Furukawa, T. A., & Cipriani, A. (2008). Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. Canadian Medical Association Journal, 178 (3), 296–305. Obach, R. S., Cox, L. M., & Tremaine, L. M. (2005). Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metabolism & Disposition, 33, 262. Kendirci, M., Salem, E., & Hellstrom, W. J. (2007). Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Ther Clin Risk Manag, 3 (2), 277–289. Deecher, D. C., Beyer, C. E., Johnston, G., Bray, J., Shah, S., Abou-Gharbia, M., & Andree, T. H. (2006). Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor. J. Pharmacol. Exp. Ther., 318 (2), 657–665. Iyengar, S., Webster, A. A., Hemrick-Luecke, S. K., Xu, J. Y., & Simmons, R. M. (2004). Efficacy of Duloxetine, a Potent and Balanced Serotonin-Norepinephrine Reuptake Inhibitor in Persistent Pain Models in Rats. J. Pharmacol. Exp. Ther., 311 (2), 576–584. Nonogaki, K., Nozue, K., Kuboki, T., & Oka, Y. (2007). Milnacipran, a serotonin and norepinephrine reuptake inhibitor, induces appetite-suppressing effects without inducing hypothalamic stress responses in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 292 (5), R1775–81. Yardley, J. P., Husbands, G. E., Stack, G., Butch, J., Bicksler, J., Moyer, J. A., Muth, E. A., Andree, T., Fletcher, H. 3rd, James, M. N., Sielecki, A. R. (1990). 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity. J. Med. Chem., 33 (10), 2899-2905. Unni, J. C. (2006). Atomoxetine. Indian Pediatrics, 43 (7), 603–606. Müller-Oerlinghausen, B., & Rüther, E. (1979). Clinical profile and serum concentration of viloxazine as compared to amitriptyline. Pharmakopsychiatrie, Neuro-Psychopharmakologie, 12 (4), 321–337. Edwards, D. M., Pellizzoni, C., Breuel, H. P., Berardi, A., Castelli, M.G., Frigerio, E., Poggesi, I., Rocchetti, M., Dubini, A., Strolin Benedetti, M. (1995). Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharmaceutics & Drug Disposition, 16 (6), 443–460. Gillman, P. K. (2007). Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology, 151 (6), 737–748. Schredla, M., Bergerb, M., & Riemannb, D. (2009). The effect of trimipramine on dream recall and dream emotions in depressive outpatients. Psychiatry Research, 167 (3), 279-286. Barbui, C., & Hotopf, M. (2001). Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. The British Journal of Psychiatry: the Journal of Mental Science, 178, 129–144. Hajak, G., Rodenbeck, A., Voderholzer, U., Riemann, D., Cohrs, S., Hohagen, F., Berger, M., & Rüther, E. (2001). Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry, 62 (6), 453–463. Albert, U., Aguglia, E., Maina, G., & Bogetto, F. (2002). Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry, 63 (11), 1004–1009. Lepola, U., Arató, M., Zhu, Y., & Austin, C. (2003). Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry, 64 (6), 654–662. Duramed Pharmaceuticals, Inc. (2007). Protriptyline drug facts. Pomona, New York: Barr Pharmaceuticals, Inc. Mayo Clinic. (2010). Depression (major depression) – Treatments and drugs. May 19, 2010, from http://www.mayoclinic.com/health/depression/DS00175/DSECTION=treatments-and-drugs Fagervall, I., & Ross, S. B. (1986). Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Biochemical Pharmacology, 35 (8), 1381–1387. Volz, H. P. (1998) Monoamine Oxidase Inhibitors A Perspective on Their Use in The Elderly. Biochemical Pharmacology, 5, 341-352. Parke-Davis Division of Pfizer Inc. (2007). Nardil® (Phenelzine Sulfate Tablets, USP), labeling information. Retrieved May 19, 2010, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf Wlliams, D. A., William, O. F., & Lemke, T. L. (2007). Foye's Principles of Medicinal Chemistry. Hagerstwon, MD: Lippincott Williams & Wilkins. Reevaluation of Tranylcypromine Sulfate. (1964). Journal of American Medical Association, 189 (10), 763-764. Amsterdam, J. D. (2003). A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Journal of Clinical Psychiatry, 64 (2), 208–214. Cascade, E. F., & Kalali, A. H. (2007). EMSAM: The First Year. Psychiatry, June 2007. Nair, N. P., Ahmed, S. K., Kin, N. M. (1993). Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. Journal of Psychiatry & Neuroscience, 18 (5), 214–225. Eli Lilly and Company. (2009). Zyprexa® Olanzapine Full Prescribing Information. U.S. Food and Drug Administration. (2006). FDA Approves the First Drug to Treat Irritability Associated with Autism, Risperdal. Retrieved May 20, 2010 from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm Croissant, B., Klein, O., Gehrlein, L., Kniest, A., Hermann, D., Diehl, A., & Mann, K. (2006). Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry, 21 (8), 570–573. Nose, M. & Barbui, C. (2003). Clinical interventions for treatment non-adherence in psychosis: meta-analysis. The British Journal of Psychiatry, 183, 197-206. What are the real risks of antidepressants? (2010). Harvard Medical School – Harvard Health Publications. Retrieved June 19, 2010 from http://www.health.harvard.edu/newsweek/What_are_the_real_risks_of_antidepressants.htm 林淑貞. 憂鬱症藥物的治療趨勢. Olyaei, A. (2005). Comparison of Commonly Used Antidepressants. American Pharmaceutical Association. (2004). Drug Information Handbook, 13th ed. Washington, DC: American Pharmaceutical Association, 1574–1575. Wang, J. G., Li, F., Zhou, H. J., Sun, P. C., Ding, D. T., & Chen, T. H. (2009). Silica Hollow Spheres with Ordered and Radially Oriented Amino-Functionalized Mesochannels. Chemistry of Materials, 21 (4), 612-620. Slowing, I. I., Vivero-Escoto, J. L., Wu, C. W., & Lin, V. S. Y. (2008). Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Advanced Drug Delivery Review, 60, 1278-1288. Hata, H., Saeki, S., Kimura, T., Sugahara, Y., & Kuroda, K. (1999). Adsorption of taxol into ordered mesoporous silicas with various pore diameters. Chem Mater, 11, 1110–1119. Luan, Z., Hartmann, M., Zhao, D., Zhou, W., & Kevan, L. (1999). Alumination andion exchange of mesoporous SBA-15 molecular sieves. Chem Mater, 11, 1621–1627. Anderson, I. M., Ferrier, I. N., Baldwin, R. C., Cowen, P. J., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R. H., Peveler, R. C., Scott, J., & Tylee, A. (2008). Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 1-54. Sousa, A., Souza, K. C., & Sousa, E. M. B. (2008). Mesoporous silica/apatite nanocomposite: special synthesis route to control local drug delivery. Acta Biomaterialia, 4, 671-679. MaHam, A., Tang, Z., Wu, H., Wang, J., & Lin, Y. (2009). Protein-Based Nanomedicine Platforms for Drug Delivery. Small, 5 (15), 1706-1721. McGee, H. (2004). On Food and Cooking: The Science and Lore of the Kitchen. New York: Scribner. Ohara, T., Sato, T., Shimizu, N., Schwind, G. P. H., Weiberg, O., Marten, K., & Greim, H. (2003). Acrylic Acid and Derivatives. Ullmann's Encyclopedia of Industrial Chemistry. Retrieved May 16, 2010 from 10.1002/14356007.a01_161.pub2 Wikipedia – The Free Encyclopedia. (2010). Acrylic acid. Retrieved May 16, 2010 from http://en.wikipedia.org/wiki/File:Acrylic-acid-2D-skeletal.png Beare-Rogers, J., Dieffenbacher, A., & Holm, J. V. (2001). IUPAC Lexicon of Lipid Nutrition. Pure Appl. Chem., 73 (4), 685-744. Burr, G. O., Burr, M. M., & Miller, E. S. (1932). On the nature and role of the fatty acids essential in nutrition. Journal of Biological Chemistry, 86 (587), 1-9. Streitwieser, J. & Heathcock, C. H. (1981). Introduction to Organic Chemistry. Macmillan, New York. Ip, C., Chin, S. F., Scimeca, J. A., & Pariza, M. W. (1991). Mammary Cancer Prevention by Conjugated Dienoic Derivative of Linoleic Acid. Cancer Research, 51, 6118-6124. Kosorok, M. R., van Egmond, A. W. A., Koscik, R., Laxova, A., & Farrell, P. M. (1996). Effect of linoleic acid intake on growth of infants with cystic fibrosis. The American Journal of Clinical Nutrition, 63 (5), 746-752. Horrobin, D. F. (1993). Fatty acid metabolism in health and disease: the role of Δ-6-desaturase. American Journal of Clinical Nutrition, 57, 732S-7S. Wikipedia – The Free Encyclopedia. (2010). Linoleic acid. Retrieved May 17, 2010 from http://en.wikipedia.org/wiki/File:LAnumbering.png Gupta, A. K., & Gupta, M. (2005). Reviews: Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 26, 3995-4021. Ratner, B. D. (1995). Surface modification of polymer: chemical, biological and surface analytical challenges. Biosensors & Bioelectronics, 10, 797-804. Choi, H. W., Lee, H. J., Kim, K. J., Kim, H. M., & Lee, S. C. (2006). Surface modification of hydroxyapatite nanocrystals by grafting polymers containing phosphonic acid groups. Journal of Colloid and Interface Science, 304, 277–281. Wang, R. Z. WebCT Notes – Chapter 2 & 3 Scanning Electron Microscope. University of British Columbia. Wang, R. Z. WebCT Notes – Chapter 4 & 5 Scanning Electron Microscope Energy Dispersive X-Ray Spectroscopy (EDS). University of British Columbia. UCSB – Materials Research Laboratory. (2009). MRL Microscopy and Microanalysis Facility. Retrieved September 20, 2009 from http://www.mrl.ucsb.edu/mrl/centralfacilities/microscopy/SEM_XL40.jpg Wikipedia – The Free Encyclopedia. (2009). Centrifuge. Retrieved September 20, 2009 from http://en.wikipedia.org/wiki/Centrifuge Omega Engineering. (2010). Introduction to pH. Retrieved September 21, 2009 from http://www.omega.com/techref/ph.html Jillavenkatesa, A., Dapkunas, S. J., Lum, L. S. (2001). Particle Size Characterization. NIST Special Publication, 960-961. Sivakugan, N. (2000). Soil Classification. James Cook University Geoengineering lecture handout. Malvern Instruments. (2010). Zetasizer Nano Series. Retrieved May 13, 2010 from http://www.malvern.com/LabEng/products/zetasizer/zetasizer_nano.htm Compute Scotland. (2008). Malvern Instruments plays its part in assessment of nanparticle reference material. Retrieved May 13, 2010 from http://www.computescotland.com/1795.php Brunauer, S., Emmett, P. H., & Teller, E. (1938). Adsorption of Gases in Multimolecular Layers. Journal of the American Chemical Society, 60, 309-319. Langmuir, I. (1916). The constitution and fundamental properties of solids and liquids, part i. solids. Journal of the American Chemical Society, 38 (11), 2221–2295. Henderson, A. P., Seetohul, L. N., Dean, A. K., Russell, P., Pruneanu, S., & Ali, Z. (2009). A Novel Isotherm, Modelling Self-Assembled Monolayer Adsorption and Structural Changes, Langmuir, 25 (2), 931–938. Fletcher, A. (2008). Porosity and Sorption Behaviour. Retrieved October 24, 2009 from http://www.staff.ncl.ac.uk/a.j.fletcher/adsorption.htm#top University of Michigan. (2005). Materials Science and Engineering. Retrieved May 14, 2010 from http://www.mse.engin.umich.edu/people/faculty/laine/facilities Scintag. (1999). Chapter 7: Basics of X-ray Diffraction. Shafranovskii, I. I., & Belov, N. V. (1962). 50 Years of X-Ray Diffraction, ed. Paul Ewald, (Springer), 351. Wang, R. Z. WebCT Notes – Chapter 1 X-Ray Diffraction (XRD). University of British Columbia. Evans Analytical Group. (2010). Thermogravimetric Analysis (TGA)/Differential Thermal Analysis (DTA). Retrieved May 14, 2010 from http://www.eaglabs.com/techniques/analytical_techniques/tga_dta.php Bhadeshia, H. K. D. H. (2002). Thermal analyses techniques. Differential thermal analysis. University of Cambridge – Material Science and Metallurgy. Retrieved May 15, 2010 from http://www.msm.cam.ac.uk/phase-trans/2002/Thermal1.pdf Skoog, et al. (2007). Principles of Instrumental Analysis, 6th ed. Thomson Brooks/Cole, 169-173. Ingle, J. D. J. & Crouch, S. R. (1988). Spectrochemical Analysis. Prentice Hall, New Jersey. Wikipedia – The Free Encyclopedia. (2010). Beer-Lambert Law. Retrieved May 16, 2010 from http://en.wikipedia.org/wiki/File:Beer_lambert.png Jasco – Analytical Instruments. (2009). V-670 Spectrophotometer. Retrieved May 16, 2010 from http://www.jascoinc.com/Libraries/Page_Photo/V670DB.sflb.ashx Wu, H. C., Wang, T. W., Sun, J. S., Wang, W. S., & Lin, F. H. (2007). A novel biomagnetic nanoparticle based on hydroxyapatite. Nanotechnology, 18 (16), 165601 Gardner, I., Zahid, N., MacCrimmon, D., & Uetrecht, J. P. (1998). A Comparison of the Oxidation of Clozapine and Olanzapine to Reactive Metabolites and the Toxicity of these Metabolites to Human Leukocytes. Molecular Pharmacology, 53 (6), 991-998. Denizot, F., & Lang, R. (1983). Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. immunol. methods, 65, 55-63. BioVision, LDH-Cytotoxicity Assay Kit, Montain View: BioVision Research Products, Catalog #K311-400 Takara, Premix WST-1 Cell Proliferation Assay System, Takara, Catalog # K400 Vandervoort, J., & Ludwig, A. (2004). Preparation and evaluation of drug-loaded gelatinnanoparticles for topical ophthalmic use. European Journal of Pharmaceutics and Biopharmaceutics, 57, 251–261. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47239 | - |
| dc.description.abstract | 現今，憂鬱症對現代人而言已構成相當的威脅，而且它也是個不容輕忽的病症，至今尚未有任何方法可以防止憂鬱症的發生。因此，擁有一個值得信任的抗憂鬱症藥物就格外重要，尤其早期治療可有效預防憂鬱症惡化跟復發。
在本論文中，我們利用中孔徑氫氧基磷灰石的降解之特性作為傳輸抗憂鬱症藥物的長效載體。中孔徑的氫氧基磷灰石經過丙烯酸(Acrylic acid, AA)和亞麻油酸(Linoleic acid, LA)的表面改質後與抗憂鬱症藥物-奧氮平® (Olanzapine, OLZ)-結合，而此實驗在為期七週的體外(in vitro)已被證實有持續性的藥物釋放。最後，LDH測試可證實HAP-AA-LA-OLZ奈米粒子的毒性是相當低的，而WST-1測試則可證實HAP-AA-LA-OLZ奈米粒子對細胞不會造成任何影響。此論文是第一個用中孔徑的氫氧基磷灰石作為藥物載體之研究。 | zh_TW |
| dc.description.abstract | Depression is becoming a dangerous threat among us nowadays, and it is a major concern that cannot be neglected. Currently, there is no sure way to prevent depression. Hence, it is essential to have a reliable medication at earlier stages to prevent depression from worsening and reoccurrence of symptoms.
In this thesis report, we propose the use of mesoporous hydroxapatite (HAP) nanoparticle as a long-lasting antidepressant drug carrier for its unique attribute in biodegradability. HAP nanoparticles synthesized are surface-modified by acrylic acid (AA) and linoleic acid (LA) for various purposes. The surface-modified HAP nanoparticles are then loaded with the latest generation of antidepressant, olanzapine (Zyprexa®, OLZ). The results have indicated a steady release of drug in in vitro experiments for a 7-week period. Lastly, the relative low cytotoxicity of HAP-AA-LA-OLZ nanoparticles is proven by LDH, and WST-1 shows there is no negative effect on cell viability and cell proliferation in in vitro studies. This study is the first to report the use of hydroxyapatite as a mesoporous nanoparticle drug carrier. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T05:51:56Z (GMT). No. of bitstreams: 1 ntu-99-R97548055-1.pdf: 6060070 bytes, checksum: 4f38ceaa92366e04ef991fee9fe588d7 (MD5) Previous issue date: 2010 | en |
| dc.description.tableofcontents | TABLE OF CONTENT
Acknowledgements i Abstract ………………………………………………………………………ii 中文摘要 ……………………………………………………………………...iii CHAPTER 1 INTRODUCTION 1 1.1 Prologue 1 1.2 Depression 4 1.2.1 Causes of Depression 5 1.2.2 Severity of Depression 6 1.3 Treatment Options for Depression 7 1.3.1 Psychotherapy 7 1.3.2 Electroconvulsive Therapy 8 1.3.3 Alternative Treatments 8 1.3.4 Antidepressant Medication and Mechanism 9 1.4 Types of Antidepressants 11 1.4.1 Selective Serotonin Reuptake Inhibitors (SSRIs) 11 1.4.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 12 1.4.3 Norepinephrine (noradrenaline) Reuptake Inhibitors (NRIs) 12 1.4.4 Tricyclic Antidepressants (TCAs) 13 1.4.5 Monoamine Oxidase Inhibitor (MAOIs) 14 1.4.6 Other Antidepressants 15 1.4.7 Olanzapine (Zyprexa®) 16 1.5 Comparison of Antidepressants 18 1.6 Purpose of Study 22 CHAPTER 2 BASIC THEORY 26 2.1 Materials 26 2.1.1 Hydroxyapatite 26 2.1.2 Albumin 28 2.1.3 Acrylic Acid 29 2.1.4 Linoleic Acid 30 2.2 Surface Modification 31 2.2.1 Surface Modification of HAP Nanoparticles 31 CHAPTER 3 MATERIALS AND EXPERIMENTS 33 3.1 Experimental Equipments 33 3.2 Reagents 50 3.3 Experimental Method 52 3.3.1 Co-Precipitation Method 52 3.3.2 Surface Modification 55 3.4 Biocompatibility 58 3.4.1 LDH Assay 59 3.4.2 WST-1 Assay 61 CHAPTER 4 RESULTS AND DISCUSSIONS 63 4.1 Analysis of Mesoporous HAP Nanoparticles 63 4.1.1 X-ray Diffractometer (XRD) 63 4.1.2 Scanning Electron Microscopy (SEM) 64 4.1.3 Particle Size Distribution 67 4.2 Analysis of HAP-AA Nanoparticles 68 4.2.1 Scanning Electron Microscopy (SEM) 68 4.3 Analysis of HAP-AA-LA-OLZ Nanoparticles 71 4.3.1 TGA-DTA Results 71 4.3.2 Drug Loading 74 4.3.3 Drug Release 75 4.3.4 LDH Assay 78 4.3.5 WST-1 Assay 79 CHAPTER 5 CONCLUSION 80 REFERNCES ……………………………………………………………………..81 | |
| dc.language.iso | en | |
| dc.subject | 抗憂鬱症藥物 | zh_TW |
| dc.subject | 氫氧基磷灰石 | zh_TW |
| dc.subject | 中孔徑材料 | zh_TW |
| dc.subject | 生物可溶性 | zh_TW |
| dc.subject | 丙烯酸 | zh_TW |
| dc.subject | 亞麻油酸 | zh_TW |
| dc.subject | linoleic acid | en |
| dc.subject | antidepressant | en |
| dc.subject | hydroxyapatite | en |
| dc.subject | mesoporous nanoparticles | en |
| dc.subject | biodegradability | en |
| dc.subject | acrylic acid | en |
| dc.title | 表面修飾之中孔徑氫氧基磷灰石作為抗憂鬱症藥物載體之研究 | zh_TW |
| dc.title | Mesoporous Hydroxyapatite Nanoparticle as Antidepressant Drug Carrier | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 98-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳嘉文(Chia-Wen (Kevin),郭士民(Shyh-Ming Kuo),張淑真(Shwu-Jen Chang),姚俊旭(Chun-Hsu Yao) | |
| dc.subject.keyword | 氫氧基磷灰石,中孔徑材料,生物可溶性,丙烯酸,亞麻油酸,抗憂鬱症藥物, | zh_TW |
| dc.subject.keyword | hydroxyapatite,mesoporous nanoparticles,biodegradability,acrylic acid,linoleic acid,antidepressant, | en |
| dc.relation.page | 89 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2010-08-18 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
| Appears in Collections: | 醫學工程學研究所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-99-1.pdf Restricted Access | 5.92 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.